Study summary

The purpose of this study was to investigate a medicine for the treatment of symptoms and complications of neurogenic detrusor overactivity (NDO) in children and adolescents.

Additional Study Details

Phase
3
Product
  • Solifenacin succinate
  • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    76
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A study to assess the long term effect, safety and metabolism of a solifenacin liquid suspension in participants 5 to 18 years of age with neurogenic detrusor overactivity? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Withdrawn
      Site RU7002
      Moscow, Russian Federation, 123317
      Withdrawn
      Site CA1005
      Hamilton, ON, Canada, L8N 3Z5
      Withdrawn
      Site RU7001
      Saint Petersburg, Russian Federation, 194100
      Withdrawn
      Site FR3301
      Paris, France, 75015
      Completed
      Site BE3201
      Gent, Belgium, 9000
      Terminated
      Site PL4805
      Gdansk, Poland, 80803
      Withdrawn
      Site DE4905
      Mainz, Germany, 55101
      Completed
      Site PH6302
      Quezon City, Philippines, 1101
      Withdrawn
      Site IN9115
      Pune, India, 411040
      Completed
      Site BR5505
      Sao Jose do Rio Preto, São Paulo, Brazil, 15090-000
      Terminated
      Site HU3602
      Miskolc, Hungary, 3526
      Withdrawn
      Site IN9104
      Dehradun, India, 248140
      Withdrawn
      Site DE4903
      Bonn, Germany, 53105
      Withdrawn
      Site RU7003
      Saint Petersburg, Russian Federation, 194100
      Withdrawn
      Site NL3103
      Rotterdam, Netherlands, 3015 GJ
      Withdrawn
      Site GB4403
      Leeds, United Kingdom, LS17RFJ
      Withdrawn
      Site NL3104
      Zwolle, Netherlands, 8011 JW
      Completed
      Site MX5205
      Mexico City, Mexico, C.P. 06700
      Completed
      Site TR9002
      Izmir, Turkey, 35100
      Completed
      Site BR5506
      Curitiba, Brazil, 80240-060
      Withdrawn
      Site PL4802
      Wroclaw, Poland, 50-369
      Completed
      Site BR5504
      Campinas, Brazil, 13083-887
      Completed
      Site US1010
      Cincinnati, OH, United States, 45229-3039
      Withdrawn
      Site US1007
      Stanford, CA, United States, 94305
      Completed
      Site BR5507
      Campinas, Brazil, 13060-803
      Completed
      Site BR5503
      Porto Alegre, Brazil, 90035-903
      Withdrawn
      Site GB4402
      Stanmore, United Kingdom, HA7 4LP
      Withdrawn
      Site FR3302
      Lille, France, 59037
      Completed
      Site KR8201
      Seoul, Republic of Korea, 120752
      Completed
      Site KR8207
      Seoul, Republic of Korea, 110744
      Withdrawn
      Site GB4401
      Sheffield, South Yorkshire, United Kingdom, S10 2TH
      Withdrawn
      Site BR5502
      Sao Paulo, Brazil, 05403-000
      Completed
      Site PH6301
      Manila, Philippines, 1015
      Completed
      Site US1008
      Tarrytown, NY, United States, 10591
      Withdrawn
      Site MX5202
      Mexico City, Mexico, 04530
      Withdrawn
      Site NL3101
      Nijmegen, Netherlands, 6525 GA
      Completed
      Site PL4801
      Warszawa, Poland, 04-730
      Withdrawn
      Site TR9005
      Istanbul, Turkey, 34890
      Withdrawn
      Site US1015
      Albany, NY, United States, 12208
      Completed
      Site DK4501
      Aarhus, Denmark, 8200
      Completed
      Site TR9003
      Ankara, Turkey, 6100
      Completed
      Site MX5203
      Leon, Mexico, 37000
      Withdrawn
      Site TR9004
      Kocaeli, Turkey, 41380
      Completed
      Site PL4803
      Gdansk, Poland, 80-952
      Withdrawn
      Site DE4901
      Marburg, Germany, 35043
      Withdrawn
      Site BR5501
      Santo André, São Paulo, Brazil, 09060-650

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?